Mark Gold - Jun 1, 2022 Form 4 Insider Report for Axogen, Inc. (AXGN)

Role
Director
Signature
/s/Dr. Mark Gold
Stock symbol
AXGN
Transactions as of
Jun 1, 2022
Transactions value $
$0
Form type
4
Date filed
6/3/2022, 04:07 PM
Previous filing
Jun 3, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXGN Common Stock Options Exercise $0 +3.04K +1% $0.00 305K Jun 1, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXGN Restricted Stock Units Options Exercise $0 -3.04K -100% $0.00* 0 Jun 1, 2022 Common Stock 3.04K Direct F3, F4
transaction AXGN Restricted Stock Units Award $0 +6.46K $0.00 6.46K Jun 1, 2022 Common Stock 6.46K Direct F3, F5
transaction AXGN Stock Option (right to purchase) Award $0 +11.8K $0.00 11.8K Jun 1, 2022 Common Stock 11.8K $9.29 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This reflects the number of restricted stock units that vested on June 1, 2022.
F2 The shares of common stock for Dr. Gold include 31,900 shares held directly, 159,575 shares held jointly by Dr. Gold and his wife, indirect ownership of 22,000 shares held by Dr. Gold's spouse in revocable trusts, and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust.
F3 Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F4 Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.
F5 Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.